Loading paragraph...
Today's Biggest Stock Gainers
| Symbol | Name | Last Price | Change | % Change | Volume | Market Cap | 52-Week Range |
|---|---|---|---|---|---|---|---|
| ENGN | enGene | $9.50 | $3.49 | 58.07% | 41.1M | $307.7M | $2.65$11.14 |
| SRDX | Surmodics | $41.01 | $13.67 | 49.97% | 1.9M | $391.0M | $25.87$41.20 |
| PUBM | PubMatic | $10.77 | $3.12 | 40.78% | 95.6K | $349.8M | $7.01$17.74 |
| REAL | RealReal | $15.03 | $3.82 | 34.03% | 13M | $1.3B | $3.70$15.28 |
| XBIT | XBiotech | $3.27 | $0.82 | 33.31% | 569.5K | $74.7M | $2.09$7.64 |
| NRGV | Energy Vault | $4.63 | $1.08 | 30.28% | 9.3M | $574.6M | $0.60$4.85 |
| SIBN | SI-Bone | $19.11 | $3.43 | 21.88% | 1.2M | $676.4M | $11.70$20.05 |
| SOC | Sable Offshore | $7.25 | $1.25 | 20.83% | 7.4M | $597.0M | $4.58$35.00 |
| CYCU | Cycurion | $3.19 | $0.55 | 20.83% | 21M | $7.6M | $2.15$2,045.10 |
| TBPH | Theravance Biopharma | $18.17 | $3.09 | 20.49% | 554.6K | $759.4M | $7.90$18.32 |
Related Articles
Featured Article
Down 75% in 12 Months, Can Iovance Biotherapeutics Stock Turn Things Around?
David Jagielski|Nov 11, 2025
Iovance has a long way to go to get to a break-even point, but the company has been showing progress.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
Prosper Junior Bakiny|Nov 7, 2025
Wall Street may be overestimating these companies' potential.
This Fitness Tech Stock Has Crushed Apple's 2025 Gains -- 1 Reason Why
Lyle Daly|Oct 19, 2025
The Amazfit brand has helped Zepp Health bounce back in a big way after years of negative returns.
Better Beaten-Down Stock: Iovance Biotherapeutics vs. Teladoc Health
Prosper Junior Bakiny|Oct 17, 2025
Is there a glimmer of hope for either of these underperforming healthcare companies?
Can This Beaten-Down Stock Bounce Back?
Prosper Junior Bakiny|Sep 19, 2025
This biotech company is innovative, but the market demands more than that.
If You'd Invested $1,000 in IOVA 3 Years Ago, Here's How Much You'd Have Today
Eric Volkman|Aug 27, 2025
The company hasn't been popular among investors since winning its first FDA approval more than a year ago.
1 Beaten-Down Stock That Could Soar By 261%, According to Wall Street
Prosper Junior Bakiny|Aug 24, 2025
Time is running out for the company to mount a comeback.
Should You Buy the Dip on PubMatic Stock?
Timothy Green|Aug 13, 2025
PubMatic stock tumbled after the company's guidance fell short.
3 Stocks That Could Turn $1,000 Into $5,000 by 2030
James Brumley|Aug 9, 2025
All three of these companies are entering a period of what could produce unparalleled top- and bottom-line growth.
Is Iovance Biotherapeutics Stock Due for a Big Rally?
David Jagielski|Jul 30, 2025
The biotech stock has been picking up steam of late -- but will it last?
